Stifel lowered the firm’s price target on OrthoPediatrics (KIDS) to $32 from $40 and keeps a Buy rating on the shares. Considering the company’s mid-January preannouncement and somewhat cautious growth outlook, the Q4 earnings call was “more encouraging than we expected,” the analyst tells investors. The firm left the OrthoPediatrics earnings call “feeling both encouraged and excited for the 2025 year,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics’ Promising Growth Prospects Reinforce Buy Rating
- OrthoPediatrics Corp. Reports Strong 2024 Financial Growth
- OrthoPediatrics sees FY25 revenue $235M-$242M, consensus $240.78M
- OrthoPediatrics reports Q4 adjusted EPS (29c), consensus (26c)
- KIDS Earnings Report this Week: Is It a Buy, Ahead of Earnings?